The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- JPMA Update (3)
September 20, 2004
- JPMA Update (2)
September 13, 2004
- <New Series>
September 6, 2004
-
June 7, 2004
-
May 24, 2004
- BULLETIN
May 24, 2004
- Brand Equity in the Pharmaceutical Industry
March 8, 2004
- <Special Contribution> Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
- Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
- <New Series> Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
- <Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
- <Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
- <Special Contribution>
November 3, 2003
- <Special Contribution>
September 1, 2003
- Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…